Drug intelligence / Profile preview

SHJ002 (Dreamhawk Vision Biotech, Inc.)

Development stage: Unknown
Lead developer: Sunhawk Vision Biotech
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Ophthalmic

Overview

SHJ002 is a sterile ophthalmic solution that was evaluated in a Phase 1 dose-escalation study in pediatric subjects for the treatment of myopia. The study was designed to assess its safety and tolerability.

Other names: microRNA-328 antisense oligonucleotidemicroRNA328 antisense oligonucleotidemicroRNA 328 antisense oligonucleotidemiRNA-328 antisense oligonucleotidemiRNA328 antisense oligonucleotidemiRNA 328 antisense oligonucleotideAnti-myopia eyedrop

Beyond the preview

Go deeper on SHJ002 (Dreamhawk Vision Biotech, Inc.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHJ002 (Dreamhawk Vision Biotech, Inc.).

Explore the full profile